|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of alpha-synuclein as the first of the loci involved in Parkinson's disease and the identification of this protein in pathological deposits in other disorders has led to the suggestion that it may share pathogenic mechanisms with multiple system atrophy, Alzheimer's disease and prion disease and that these mechanisms are related to a synuclein pathway to cell death.
|
10469843 |
1999 |
|
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The beta-synuclein gene is highly homologous, expressed in the nervous system and thus is a good candidate gene for PD.
|
10430516 |
1999 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aoffa-Synuclein, a presynaptic nerve terminal protein, may be an important component of Lewy bodies in Parkinson's disease, dementia with Lewy bodies, and other neurodegenerative diseases.
|
10192768 |
1999 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We characterized beta-synuclein, the non-amyloidogenic homolog of alpha-synuclein, as an inhibitor of aggregation of alpha-synuclein, a molecule implicated in Parkinson's disease.
|
11683992 |
2001 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although a survey of the available databases suggests that there is no human splice form equivalent of rSYN2, thus arguing against a direct role in Lewy body formation and Parkinson's disease, these data nonetheless suggest that modifications of the carboxy-terminal region of -synuclein predispose it to inclusion formation.
|
11959424 |
2002 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since alterations in synuclein function may predispose to the disease pathology of PD, regardless of the presence of genetic mutations, a more thorough understanding of the cellular regulation and function of alpha-synuclein may be of crucial importance to our understanding of this degenerating disorder.
|
12025860 |
2002 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein.
|
12428718 |
2002 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
LHGDN |
Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease.
|
12867415 |
2003 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we discuss the evidence for a common pathway model of Parkinson's disease through a review of synuclein transgenic models and outline an approach for the identification of shared therapeutic targets.
|
12846984 |
2003 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we report that all three naturally occurring synuclein isoforms (alpha, beta, and gamma-synuclein) are similarly effective inhibitors of PLD2 in vitro, as is the Parkinson's disease-associated mutant A30P.
|
15033366 |
2004 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these data further support a role for beta-synuclein in regulating the conformational state of alpha-synuclein and suggest that this gene transfer approach might have potential for the development of alternative therapies for PD and DLB.
|
15483670 |
2004 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intraneuronal deposition containing alpha-synuclein is implicated in the pathogenesis of synuclein-opathies including Parkinsons disease (PD).
|
15460447 |
2004 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DNA samples from the 43 index cases were screened for alterations in the genes for alpha-synuclein and beta-synuclein, as alpha-synuclein alterations cause PD and beta-synuclein may modulate alpha-synuclein aggregation and neurotoxicity.
|
15365127 |
2004 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
First, although some of the Mendelian forms of PD are very rare (including those caused by alfa-synuclein, DJ-1, and PINK1 mutations) they are facilitating greatly the dissection of the molecular pathways that lead to death of dopaminergic neurons; these pathways might also be implicated in the pathogenesis of the common forms of PD.
|
16175160 |
2005 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
As mutations altering alpha-synuclein structure or increasing alpha-synuclein expression level can cause familial forms of PD or related Lewy body disorders, alpha-synuclein is believed to play a central role in the process of neuron toxicity, degeneration and death in "synucleinopathies". beta-synuclein is closely related to alpha-synuclein and has been shown to inhibit alpha-synuclein aggregation and ameliorate alpha-synuclein neurotoxicity.
|
16959793 |
2006 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This invariant pattern of specific phosphorylation, truncation, and ubiquitination is also present in the detergent-insoluble fraction of brain from patients with familial Parkinson's disease (synuclein A53T mutation) as well as multiple system atrophy, suggesting a common pathogenic pathway for both genetic and sporadic Lewy body diseases.
|
16847063 |
2006 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, many Lewy neurites immunopositive for phosphorylated a-synuclein were found in the nerve fascicles of the epicardium in one case examined and in Parkinson's disease cases to a lesser degree.
|
17319280 |
2007 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presence of AAb against beta-synuclein or gamma-synuclein showed no association with PD.
|
17448146 |
2007 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neither of the SNCB SNPs examined were associated with PD overall or in strata, and haplotype analyses were negative as well.
|
17556099 |
2007 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The discovery of three mutants in the -synuclein (alphaSyn) gene and the identification of alphaSyn as the major component of Lewy body have opened a new field for understanding the pathogenesis of Parkinson's disease (PD).
|
17209570 |
2007 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alpha- and beta-synuclein are closely related proteins, the first of which is associated with deposits formed in neurodegenerative conditions such as Parkinson's disease while the second appears to have no relationship to any such disorders.
|
18436957 |
2008 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The synuclein family recently came into the spotlight when one of its members, alpha-synuclein, was linked both genetically and neuropathologically to Parkinson's disease.
|
19081538 |
2008 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease.
|
19351880 |
2009 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the attempt to better reproduce the key features of PD, in particular the progressive nature of neurodegeneration, alternative PD models have been developed, based on the genetic and neuropathological links between -synuclein ( -syn) and PD.
|
20522009 |
2010 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that variants in all 3 members of the synuclein gene family, particularly SNCA and SNCG, affect the risk of developing DLBD and warrant further investigation in larger, pathologically defined data sets as well as clinically diagnosed Parkinson disease/dementia with Lewy bodies case-control series.
|
20697047 |
2010 |